U.S. Court rules Merck's Zetia patent valid

(Reuters) - A U.S. court on Friday ruled that the patent on Merck & Co's MRK.N cholesterol fighter Zetia and a related drug Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc MYL.O until the patent expires.

Mylan had admitted that its product would infringe the patent, which run until April of 2017, Merck said.